source
- Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM dealAnother $200M for Mentari: Migraine drug developer Mentari Therapeutics has lined up a second private placement as it works to close its reverse merger with InMed Pharmaceuticals. The Paragon Thera…Endpoints · 10d ago↗ source
- Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's preventionLONDON — Eli Lilly, the world’s biggest drugmaker, appears to be getting more ambitious about tackling brain diseases. Last week, the company announced it would pay $2.8 billion upfront to acquire…Endpoints · 10d ago↗ source
- FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in FoodThe U.S. Food and Drug Administration today announced two actions targeting petroleum-based color additives in food, continuing the agency’s broader efforts to Make America Healthy Again.